IGC Pharma, Inc. - COM NEW (IGC)

CUSIP: 45408X308

Q1 2020 13F Holders as of 31 Mar 2020

Type / Class
Equity / COM NEW
Total 13F shares
1,419,568
Share change
-72,211
Total reported value
$693,000
Price per share
$0.49
Number of holders
12
Value change
-$52,354
Number of buys
1
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 45408X308?
CUSIP 45408X308 identifies IGC - IGC Pharma, Inc. - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of IGC - IGC Pharma, Inc. - COM NEW (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
VANGUARD GROUP INC
13F
Company
class O/S missing
454,110
$286,000 31 Dec 2019
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
class O/S missing
261,671
$164,000 31 Dec 2019
13F
Carroll Financial Associates, Inc.
13F
Company
class O/S missing
215,000
$135,000 31 Dec 2019
13F
DEARBORN PARTNERS LLC
13F
Company
class O/S missing
102,760
$65,000 31 Dec 2019
13F
Virtu Financial LLC
13F
Company
class O/S missing
98,050
$62,000 31 Dec 2019
13F
NORTHERN TRUST CORP
13F
Company
class O/S missing
93,597
$59,000 31 Dec 2019
13F
Creative Planning
13F
Company
class O/S missing
90,449
$57,000 31 Dec 2019
13F
GOLDMAN SACHS GROUP INC
13F
Company
class O/S missing
66,280
$42,000 31 Dec 2019
13F
BANK OF MONTREAL /CAN/
13F
Company
class O/S missing
45,000
$28,000 31 Dec 2019
13F
Sowell Financial Services LLC
13F
Company
class O/S missing
37,305
$24,000 31 Dec 2019
13F
TRUIST FINANCIAL CORP
13F
Company
class O/S missing
36,667
$23,000 31 Dec 2019
13F
BlackRock Finance, Inc.
13F
Company
class O/S missing
34,254
$22,000 31 Dec 2019
13F
CITADEL ADVISORS LLC
13F
Company
class O/S missing
14,735
$9,000 31 Dec 2019
13F
UBS Group AG
13F
Company
class O/S missing
12,829
$8,000 31 Dec 2019
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
class O/S missing
10,794
$7,000 31 Dec 2019
13F
Cambridge Investment Research Advisors, Inc.
13F
Company
class O/S missing
10,250
$6,000 31 Dec 2019
13F
GROUP ONE TRADING LLC
13F
Company
class O/S missing
3,578
$2,000 31 Dec 2019
13F
MORGAN STANLEY
13F
Company
class O/S missing
2,500
$2,000 31 Dec 2019
13F
Geneos Wealth Management Inc.
13F
Company
class O/S missing
3,200
$1,000 31 Dec 2019
13F

Institutional Holders of IGC Pharma, Inc. - COM NEW (IGC) as of Q1 2020

As of 31 Mar 2020, IGC Pharma, Inc. - COM NEW (IGC) was held by 12 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,419,568 shares. The largest 10 holders included VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Carroll Financial Associates, Inc., DEARBORN PARTNERS LLC, BlackRock Inc., NORTHERN TRUST CORP, GOLDMAN SACHS GROUP INC, BANK OF MONTREAL /CAN/, Sowell Financial Services LLC, and TRUIST FINANCIAL CORP. This page lists 12 institutional shareholders reporting positions in this security for the Q1 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2020 vs Q4 2019 Across Filers

Q4 2019 holders
17
Q1 2020 holders
12
Holder diff
-5
Investor Q4 2019 Shares Q1 2020 Shares Share Diff Share Chg % Q4 2019 Value $ Q1 2020 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .